FranÃ§ois Mullier

List of Publications by Year
in descending order

169 papers	12,900 citations	76031 42 h-index	29333 108 g-index
180 all docs	180 docs citations	180 times ranked	19985 citing authors

#	Article	IF	Citations
1	D-dimer: old dogmas, new (COVID-19) tricks. Clinical Chemistry and Laboratory Medicine, 2023, 61, 841-850.	1.4	17
2	Study of in vitro thrombin generation after neutralization of heparin. International Journal of Laboratory Hematology, 2022, 44, 168-176.	0.7	8
3	Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US. Infection, 2022, 50, 531-536.	2.3	16
4	Multicentre evaluation of 5B9, a monoclonal antiâ€PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2022, 20, 252-259.	1.9	5
5	Effect of tissue factor pathway inhibitor on thrombin generation assay. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0
6	Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement. Journal of Clinical Medicine, 2022, 11, 1338.	1.0	4
7	Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. Frontiers in Cardiovascular Medicine, 2022, 9, 864899.	1.1	1
8	The edoxabanâ€M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12680.	1.0	1
9	Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant. Viruses, 2022, 14, 654.	1.5	44
10	Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply â€˜hyperfibrinolysisâ€™. Thrombosis Research, 2022, 214, 63-64.	0.8	3
11	Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19â€”BNT162b2 mRNA Vaccination. Viruses, 2022, 14, 1470.	1.5	5
12	Are the DOAC plasma level thresholds appropriate for clinical decisionâ€making? A reappraisal using thrombin generation testing. International Journal of Laboratory Hematology, 2021, 43, e48-e51.	0.7	11
13	Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thrombosis Research, 2021, 197, 20-23.	0.8	36
14	Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. International Journal of Laboratory Hematology, 2021, 43, 7-20.	0.7	23
15	Antibody titres decline 3-month post-vaccination with BNT162b2. Emerging Microbes and Infections, 2021, 10, 1495-1498.	3.0	141
16	Influence of C-reactive protein on thrombin generation assay. Clinical Chemistry and Laboratory Medicine, 2021, 59, e301-e305.	1.4	1
17	Pseudothrombocytopeniaâ€”A Review on Causes, Occurrence and Clinical Implications. Journal of Clinical Medicine, 2021, 10, 594.	1.0	29
18	Analytical and clinical evaluation of four commercial SARS-CoV-2 serological immunoassays in hospitalized patients and ambulatory individuals. Journal of Virological Methods, 2021, 289, 114060.	1.0	9

#	Article	IF	Citations
19	Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study. TH Open, 2021, 05, e152-e154.	0.7	9
20	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 1740.	1.0	43
21	Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: Impact on plasma drug levels. Thrombosis Research, 2021, 201, 139-142.	0.8	3
22	Comparison is not reason: Pitfalls in reporting thrombin generation results in anticoagulated patients. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12523.	1.0	0
23	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. Chest, 2021, 159, 2417-2427.	0.4	54
24	Heparinâ€induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. Journal of Thrombosis and Haemostasis, 2021, 19, 1959-1972.	1.9	14
25	Prothrombotic Disturbances of Hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Study. , 2021, 41, .		0
26	Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2. Microorganisms, 2021, 9, 1340.	1.6	33
27	Impact of centrifugation on thrombin generation in healthy subjects and in patients treated with direct oral anticoagulants. International Journal of Laboratory Hematology, 2021, 43, 1585-1592.	0.7	2
28	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thrombosis Research, 2021, 203, 163-171.	0.8	52
29	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica, 2021, 106, 3249-3252.	1.7	9
30	Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021). Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100919.	0.6	12
31	NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. Frontiers in Pharmacology, 2021, 12, 708302.	1.6	37
32	Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study. Thrombosis Research, 2021, 205, 8-10.	0.8	6
33	Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clinical Microbiology and Infection, 2021, 27, 1351.e5-1351.e7.	2.8	54
34	Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. Vaccines, 2021, 9, 1092.	2.1	96
35	The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. American Journal of Medicine, 2021, 134, 1295-1299.	0.6	16
36	Post-SARS-CoV-2 vaccination specific antibody decrease â€" Thresholds for determining seroprevalence and seroneutralization differ. Journal of Infection, 2021, 83, e4-e5.	1.7	20

#	Article	IF	Citations
37	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica, 2021, , .	1.7	1
38	Concentrations of direct oral anticoagulants according to guidelines for the periprocedural management of low bleeding risk procedures. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 121-122.	0.6	2
39	Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants. Thrombosis Research, 2020, 185, 72-77.	0.8	5
40	Utility of the XNâ€1000 research mode for leukocytes counting in ascitic and pleural fluids. International Journal of Laboratory Hematology, 2020, 42, e92-e95.	0.7	4
41	Evaluation of a hereditary spherocytosis screening algorithm by automated blood count using reticulocytes and erythrocytic parameters on the Sysmex XNâ€series. International Journal of Laboratory Hematology, 2020, 42, e88-e91.	0.7	6
42	Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. Data in Brief, 2020, 33, 106519.	0.5	19
43	Effects of Time-Interval since Blood Draw and of Anticoagulation on Platelet Testing (Count, Indices) Tj ETQq1 1 0.784314 rgBT /Over Clinical Medicine, 2020, 9, 2515.	1.0	17
44	Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thrombosis Journal, 2020, 18, 17.	0.9	52
45	Advances in Platelet Function Testingâ€"Light Transmission Aggregometry and Beyond. Journal of Clinical Medicine, 2020, 9, 2636.	1.0	31
46	Studies on hemostasis in COVIDâ€19 deserve careful reporting of the laboratory methods, their significance, and their limitations. Journal of Thrombosis and Haemostasis, 2020, 18, 3121-3124.	1.9	16
47	Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers, 2020, 12, 1242.	1.7	9
48	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Critical Care, 2020, 24, 364.	2.5	118
49	Twoâ€site evaluation of a new workflow for the detection of malignant cells on the Sysmex XNâ€1000 body fluid analyzer. International Journal of Laboratory Hematology, 2020, 42, 544-551.	0.7	6
50	Reduction of Preoperative Waiting Time Before Urgent Surgery for Patients on P2Y12 Inhibitors Using Multiple Electrode Aggregometry: A Retrospective Study. Journal of Clinical Medicine, 2020, 9, 424.	1.0	4
51	Assessment of low plasma concentrations of apixaban in the periprocedural setting. International Journal of Laboratory Hematology, 2020, 42, 394-402.	0.7	5
52	Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia. Journal of Clinical Medicine, 2020, 9, 1226.	1.0	34
53	Diagnosis and management of heparin-induced thrombocytopenia. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 291-310.	0.6	45
54	Evaluation of a new thromboplastin reagent STAâ€NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time, international normalized ratio and extrinsic factor levels. International Journal of Laboratory Hematology, 2020, 42, 650-660.	0.7	6

#	Article	IF	Citations
55	Clustering and Kernel Density Estimation for Assessment of Measurable Residual Disease by Flow Cytometry. Diagnostics, 2020, 10, 317.	1.3	0
56	Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation. Thrombosis Research, 2019, 184, 8-15.	0.8	4
57	Two-site evaluation of high-fluorescent cells for the detection of malignant cells: The importance of clinical information. Clinica Chimica Acta, 2019, 493, S428-S429.	0.5	0
58	Toward standardization of assays measuring extracellular vesicleâ€associated tissue factor activity. Journal of Thrombosis and Haemostasis, 2019, 17, 1261-1264.	1.9	10
59	Assessment of the analytical performances and sample stability on ST Genesia system using the STG â€DrugScreen application. Journal of Thrombosis and Haemostasis, 2019, 17, 1273-1287.	1.9	43
60	Clotting test results correlate better with DOAC concentrations when expressed as a â€œCorrection Ratioâ€ results before/after extraction with the DOAC Stop reagent. Thrombosis Research, 2019, 179, 69-72.	0.8	9
61	Andexanet alfa for the reversal of factor Xa inhibitors. Expert Opinion on Biological Therapy, 2019, 19, 387-397.	1.4	10
62	Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents. International Journal of Laboratory Hematology, 2019, 41, 316-324.	0.7	9
63	Extracellular Vesicles in Red Blood Cell Concentrates: An Overview. Transfusion Medicine Reviews, 2019, 33, 125-130.	0.9	21
64	Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab. Medicine (United States), 2019, 98, e16164.	0.4	2
65	Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. International Journal of Laboratory Hematology, 2019, 41, 250-261.	0.7	9
66	Measurement of factor VIII activity of efraloctocog alfa with commercially available oneâ€stage clotting and chromogenic assays: Results from the Belgian national External Quality Assessment Scheme. International Journal of Laboratory Hematology, 2019, 41, e20-e22.	0.7	2
67	Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. Journal of Thrombosis and Haemostasis, 2018, 16, 1236-1245.	1.9	130
68	Evaluation of the Fully Automated HemosIL Acustar ADAMTS13 Activity Assay. Thrombosis and Haemostasis, 2018, 118, 942-944.	1.8	23
69	BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?. TH Open, 2018, 02, e68-e88.	0.7	21
70	Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases, 2018, 111, 210-223.	0.7	22
71	A reminder of the place of morphology and the Hâ€score in the diagnosis of hemophagocytic lymphohistiocytosis (<scp>HLH</scp>). Clinical Case Reports (discontinued), 2018, 6, 527-528.	0.2	2
72	A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN^{TM} analyzers in routine laboratory practice. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 159-164.	0.6	14

#	Article	IF	Citations
73	Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 379-389.	0.6	25
74	The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. Thrombosis Research, 2018, 168, 63-66.	0.8	14
75	Position du GIHP sur les tests viscoÃ©lastiquesÂ: quelle place pour quelle indication en situation hÃ©morragiqueÂ?. AnesthÃ©sie & RÃ©animation, 2018, 4, 452-464.	0.1	0
76	Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 129-138.	0.7	22
77	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Haemostasis, 2018, 16, 209-219.	1.9	266
78	European guidelines on perioperative venous thromboembolism prophylaxis. European Journal of Anaesthesiology, 2018, 35, 96-107.	0.7	15
79	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thrombosis Journal, 2018, 16, 28.	0.9	63
80	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	5.5	6,961
81	D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 548-577.	2.7	116
82	Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2526-2529.	1.9	14
83	The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation. Thrombosis Research, 2018, 171, 160-166.	0.8	21
84	Development and validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of serotonin and thromboxane B2 from activated platelets. International Journal of Laboratory Hematology, 2018, 40, 663-671.	0.7	4
85	Evaluation of the DOAC-StopÂ® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. TH Open, 2018, 02, e202-e209.	0.7	54
86	Betrixaban: Impact on Routine and Specific Coagulation Assaysâ€"A Practical Laboratory Guide. Thrombosis and Haemostasis, 2018, 118, 1203-1214.	1.8	21
87	Reduction of the turnâ€around time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. International Journal of Laboratory Hematology, 2018, 40, e105-e108.	0.7	10
88	Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. Blood Transfusion, 2018, 16, 163-172.	0.3	4
89	Persistent heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 2017, 28, 193-197.	0.5	10
90	Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. Journal of Thrombosis and Thrombolysis, 2017, 43, 224-232.	1.0	21

#	Article	IF	Citations
91	Usefulness of thresholds for smear review of neutropenic samples analyzed with a Sysmex XN-10 analyzer. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 406-409.	0.6	4
92	Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels. Thrombosis Research, 2017, 156, 36-38.	0.8	25
93	Perioperative management of patients on direct oral anticoagulants. Thrombosis Journal, 2017, 15, 14.	0.9	92
94	Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thrombosis Research, 2017, 156, 142-148.	0.8	7
95	Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. International Journal of Laboratory Hematology, 2017, 39, 402-408.	0.7	24
96	Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. Expert Opinion on Biological Therapy, 2017, 17, 1275-1296.	1.4	10
97	Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. European Heart Journal, 2017, 38, 2431-2439.	1.0	106
98	An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. Thrombosis Research, 2017, 157, 29-37.	0.8	14
99	Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2017, 16, 5-12.	1.0	48
100	Impact of the Direct Oral Anticoagulants on Activated Clotting Time. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, e24-e27.	0.6	15
101	From XE-2100 to XN-9000, from SIS Standard to GFHC recommendations for slide review: potential impact on review rate and turnaround time. Annales De Biologie Clinique, 2017, 75, 285-292.	0.2	0
102	Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review. Molecules, 2017, 22, 617.	1.7	61
103	Edoxaban: Impact on routine and specific coagulation assays. Thrombosis and Haemostasis, 2016, 115, 368-381.	1.8	61
104	Evaluation and optimization of the extended information process unit (E-IPU) validation module integrating the sysmex flag systems and the recommendations of the French-speaking cellular hematology group (GFHC). Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 465-471.	0.6	9
105	Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories. Thrombosis Journal, 2016, 14, 49.	0.9	88
106	Heparin monitoring: clinical outcome and practical approach. Annales De Biologie Clinique, 2016, 74, 637-652.	0.2	4
107	Usefulness of Flow Cytometric Mepacrine Uptake/Release Combined with CD63 Assay in Diagnosis of Patients with Suspected Platelet Dense Granule Disorder. Seminars in Thrombosis and Hemostasis, 2016, 42, 282-291.	1.5	30
108	Heparinâ€induced multiâ€electrode aggregometry method for heparinâ€induced thrombocytopenia testing: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 2548-2552.	1.9	48

#	Article	IF	Citations
109	Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests. Regional Anesthesia and Pain Medicine, 2016, 41, 787-788.	1.1	5
110	Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival. JAMA Oncology, 2016, 2, 625.	3.4	158
111	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. TrAC - Trends in Analytical Chemistry, 2016, 84, 41-50.	5.8	17
112	Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 1166-1168.	1.9	3
113	Influence of dabigatran and rivaroxaban on routine coagulation assays. Thrombosis and Haemostasis, 2015, 113, 154-164.	1.8	73
114	The euglobulin clot lysis time to assess the impact of nanoparticles on fibrinolysis. Journal of Nanoparticle Research, 2015, 17, 1.	0.8	1
115	Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. BioMed Research International, 2015, 2015, 1-13.	0.9	35
116	Estimation of dabigatran plasma concentrations in the perioperative setting. Thrombosis and Haemostasis, 2015, 113, 862-869.	1.8	53
117	Dose tailoring of dabigatran etexilate: obvious or excessive?. Expert Opinion on Drug Safety, 2015, 14, 1283-1289.	1.0	22
118	Criteria for Prescribing Dabigatran Etexilate and Rivaroxaban Really Appropriate? Authorsâ€™ Reply. Annals of Pharmacotherapy, 2015, 49, 155-155.	0.9	1
119	Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. European Journal of Haematology, 2015, 95, 190-198.	1.1	85
120	Tips and tricks for flow cytometry-based analysis and counting of microparticles. Transfusion and Apheresis Science, 2015, 53, 110-126.	0.5	67
121	Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. Thrombosis Research, 2015, 136, 693-696.	0.8	28
122	EVpedia: a community web portal for extracellular vesicles research. Bioinformatics, 2015, 31, 933-939.	1.8	317
123	Platelet microparticle generation assay for heparin-induced thrombocytopenia diagnosis: How should we express the results?. Thrombosis Research, 2015, 136, 175-177.	0.8	6
124	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thrombosis Research, 2015, 135, 852-860.	0.8	26
125	Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy. Haematologica, 2015, 100, 1023-30.	1.7	14
126	Remodeling and Repair in Rhinosinusitis. Current Allergy and Asthma Reports, 2015, 15, 34.	2.4	17

#	Article	IF	Citations
127	Erratum to â€œPreventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulantsâ€. BioMed Research International, 2014, 2014, 1-1.	0.9	8
128	Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. Journal of Extracellular Vesicles, 2014, 3, .	5.5	13
129	Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. BioMed Research International, 2014, 2014, 1-16.	0.9	23
130	Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants. BioMed Research International, 2014, 2014, 1-14.	0.9	6
131	Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation. Annals of Pharmacotherapy, 2014, 48, 1258-1268.	0.9	81
132	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thrombosis Journal, 2014, 12, 24.	0.9	45
133	Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department. Blood Coagulation and Fibrinolysis, 2014, 25, 309-315.	0.5	30
134	Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and Allâ€Cause Mortality: A Systematic Review and Metaâ€analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2014, 3, e000515.	1.6	85
135	Platelet microparticle generation assay: A valuable test for immune heparin-induced thrombocytopenia diagnosis. Thrombosis Research, 2014, 133, 1068-1073.	0.8	36
136	A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: A practical guide. Nanotoxicology, 2014, 8, 220-232.	1.6	11
137	Microparticle bearing tissue factor: A link between promyelocytic cells and hypercoagulable state. Thrombosis Research, 2014, 133, 433-439.	0.8	35
138	Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thrombosis Research, 2014, 134, 213-214.	0.8	3
139	Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. Thrombosis Research, 2014, 133, 1074-1078.	0.8	23
140	The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review. Journal of Extracellular Vesicles, 2014, 3, .	5.5	14
141	Impact of Silver Nanoparticles on Haemolysis, Platelet Function and Coagulation. Nanobiomedicine, 2014, 1, 4.	4.4	67
142	Estimation of Dabigatran Plasma Concentrations in the Perioperative Setting. an Ex-Vivo Study Using Dedicated Coagulation Assays. Blood, 2014, 124, 1549-1549.	0.6	1
143	Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: A retrospective study. Thrombosis Research, 2013, 132, 352-359.	0.8	25
144	Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thrombosis and Haemostasis, 2013, 110, 283-294.	1.8	179

#	Article	IF	Citations
145	Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. Journal of Thrombosis and Haemostasis, 2013, 11, 1190-1193.	1.9	287
146	Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions. Journal of Thrombosis and Haemostasis, 2013, 11, 693-696.	1.9	59
147	Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. Blood Coagulation and Fibrinolysis, 2013, 24, 567-572.	0.5	16
148	Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thrombosis and Haemostasis, 2013, 110, 543-549.	1.8	92
149	Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thrombosis and Haemostasis, 2013, 110, 723-731.	1.8	141
150	Bioactivity and hemocompatibility study of amorphous hydrogenated carbon coatings produced by pulsed magnetron discharge. Journal of Biomedical Materials Research - Part A, 2013, 101A, 1800-1812.	2.1	10
151	Characterisation of tissue factorâ€bearing extracellular vesicles with AFM: comparison of airâ€tappingâ€mode AFM and liquid Peak Force AFM. Journal of Extracellular Vesicles, 2013, 2, .	5.5	74
152	Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. Journal of Extracellular Vesicles, 2013, 2, 19728.	5.5	24
153	Is Dilute Russellâ€™s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?. Blood, 2013, 122, 3634-3634.	0.6	0
154	Dabigatran Etexilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. Blood, 2013, 122, 3633-3633.	0.6	0
155	Is Thrombin Time Useful To Guide Peri-Procedural Management For Patients On Dabigatran Etexilate?: An In Vitro Validation Study. Blood, 2013, 122, 2388-2388.	0.6	0
156	Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. Nanotoxicology, 2012, 6, 213-232.	1.6	24
157	The Effect of Clonidine, an Alpha-2 Adrenergic Receptor Agonist, on Inflammatory Response and Postischemic Endothelium Function During Early Reperfusion in Healthy Volunteers. Journal of Cardiovascular Pharmacology, 2012, 60, 553-560.	0.8	13
158	A Case of Therapy-Related Myeloid Neoplasm in a Patient with Crohnâ€™s Disease Treated with Azathioprine. Acta Haematologica, 2012, 128, 1-6.	0.7	8
159	Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thrombosis Research, 2012, 130, 956-966.	0.8	201
160	Impact of dabigatran on a large panel of routine or specific coagulation assays. Thrombosis and Haemostasis, 2012, 107, 985-997.	1.8	321
161	Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study. Annals of Hematology, 2012, 91, 203-213.	0.8	18
162	More on: calibration for the measurement of microparticles: needs, interests, and limitations of calibrated polystyrene beads for flow cytometryâ€based quantification of biological microparticles. Journal of Thrombosis and Haemostasis, 2011, 9, 1679-1681.	1.9	51

#	Article	IF	Citations
163	Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study. Annals of Hematology, 2011, 90, 759-768.	0.8	55
164	A GEIL flow cytometry consensus proposal for quantification of plasma cells: Application to differential diagnosis between MGUS and myeloma. Cytometry Part B - Clinical Cytometry, 2011, 80B, 176-185.	0.7	22
165	No effect of lysis solutions on absolute CD19+ lymphocytes count and CD45 index in chronic lymphocytic leukemia. Cytometry Part B - Clinical Cytometry, 2011, 80B, 369-372.	0.7	4
166	Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2010, 103, 1277-1281.	1.8	22
167	Apports deÂlaÂcytologie etÂdeÂlaÂcytomÃ©trie enÂflux dansÂleÂdiagnostic d'un lymphome T angio-immunoblastique (LTAI) avecÂenvahissement sanguin etÂmÃ©dullaire: cas clinique etÂrevue deÂlaÂlittÃ©rature. Hematologie, 2009, 15, 314-318.	0.0	0
168	DEFINITION OF CLINICAL THRESHOLD FOR CMV REAL-TIME PCR AFTER COMPARISON WITH PP65 ANTIGENAEMIA AND CLINICAL DATA. Acta Clinica Belgica, 2009, 64, 477-482.	0.5	3
169	Expression of a Schistosoma mansoni 28-kilodalton glutathione S-transferase in the livers of transgenic mice and its effect on parasite infection. Infection and Immunity, 1997, 65, 3867-3874.	1.0	9